This protocol is judged by an institutional overview board, an independent team that reviews any scientific trials involving humans. If a analyze consists of a Schedule I drug, as soon as the board approves the protocol as ethical, the researchers have to make an application for an investigational new drug (IND) selection with the FDA.Dihydrocodein